Trinity Biotech

Trinity Biotech Interest Coverage

The Interest Coverage Ratio of Trinity Biotech (TRIB) as of Nov 11, 2026 is -2.21. In the previous year, Interest Coverage Ratio was -2.45 — a change of -9.57% (higher).

Interest Coverage

-2.21

YoY

-9.57%

Last updated:

Interest Coverage Ratio of Trinity Biotech is 2024 -2.21 . Interest Coverage Ratio of Trinity Biotech was 2023 -2.45 . It decreases by -9.57% higher compared to the previous year.

The Trinity Biotech Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
1.19 USD
Jan 1, 2018
0.76 USD
Jan 1, 2019
0.14 USD
Jan 1, 2020
0.01 USD
Jan 1, 2021
0.56 USD
Jan 1, 2022
-0.62 USD
Jan 1, 2023
-2.45 USD
Jan 1, 2024
-2.21 USD
The Trinity Biotech Interest Coverage history
YEARInterest CoverageYoY
-2.21-9.57%
-2.45+296.36%
-0.62-211.02%
0.56+4,453.57%
0.01-91.43%
0.14-81.22%
0.76-36.31%
1.19-27.43%
1.64-56.31%
3.76-99.27%
515.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Interest Coverage Ratio of Trinity Biotech is -2.21 in 2024.

Interest Coverage Ratio of Trinity Biotech changed from -2.45 to -2.21, representing a -9.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Trinity Biotech

All Key Metrics — Trinity Biotech